BLACKSBURG, VA--(Marketwire - December 05, 2011) - Intrexon Corporation, a privately held synthetic biology engineering company, today announced the appointment of Krish S. Krishnan, M.S., M.B.A., to Chief Operating Officer. Mr. Krishnan will have overarching executive responsibility for all of Intrexon’s operating divisions.
Mr. Krishnan brings many years of experience in the life sciences industry, having held key executive roles at several companies including, most notably, his tenure as Chief Financial Officer, Chief Operating Officer and board member of New River Pharmaceuticals, Inc. Mr. Krishnan started his career as an engineer with E.I. Dupont de Nemours in Wilmington, Delaware. He received a B.S. in Mechanical Engineering from the Indian Institute of Technology, a M.S. in Engineering from The University of Toledo, and an M.B.A. in Finance from The Wharton School at the University of Pennsylvania.
Intrexon’s Chairman and CEO Randal J. Kirk welcomes Mr. Krishnan stating, “Krish has an exceptional talent for driving smart execution of high value biotech strategies, as evidenced by the fast trajectory and tremendous upside return we realized together at New River Pharmaceuticals. Krish joins Intrexon at a time when his engineering and operational leadership skills can be applied across many such opportunities and drive the robust success of our partnerships and collaborations.” Kirk continues, “I have no doubt that he will bring an even greater industrial engineering discipline to the design and metrics of our processes and, in so doing, deliver further scalability, deeper cost reductions and even faster turnaround times. It is my great pleasure to welcome Krish to the Intrexon leadership team and the opportunity to go well beyond the previous level of achievement we have attained together.”
Mr. Krishnan echoed the comments of Mr. Kirk, and added, “I am very excited to join Intrexon, and look forward to working closely with RJ to drive strong execution of this game changing biotech strategy and business model.”
About Intrexon Corporation
Intrexon Corporation is a privately held biotechnology company focused on the industrial engineering of synthetic biology. Intrexon is deploying its extensive engineering platform and capabilities to rapidly design and produce novel biofunctions and applications for human therapeutics, protein production, industrial products, agricultural biotechnology, and animal science. The company’s advanced industrial engineering platform enables Better DNA™ technology by combining revolutionary DNA control systems with corresponding advancements in modular transgene design, assembly and optimization. More information about the company is available at www.DNA.com.
Contact:
Andrew Udell
Intrexon Corporation
Phone: 301-556-9850
E-mail: Email Contact
